# Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

> **NCT03116555** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 37 (estimated)

## Conditions studied

- Metastatic Gastric Adenocarcinoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03116555
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-05
- **Primary completion:** 2020-03
- **Final completion:** 2020-09
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2019-11-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116555, "Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03116555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*